Basic Information
TYROKA FILM-COATED TABLETS 200 MG
TABLET, FILM COATED
Regulatory Information
SIN16736P
March 9, 2023
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XL01EX03
Company Information
LOTUS INTERNATIONAL PTE. LTD.
LOTUS INTERNATIONAL PTE. LTD.
Active Ingredients
Strength: 200mg
Detailed Information
Contraindications
**4.3 Contraindications** Pazopanib is contraindicated in patients with severe hepatic impairment and hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** Renal cell carcinoma (RCC) Pazopanib is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Pazopanib is indicated for the treatment of adult patients with selective subtypes of soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).